jimmy Turano

On Small Cap Drug Makers and Volatility

On Oct 19 02:31 AM Justin M. Hall wrote:

> Jimmy Turano:
>
> MRNA appears to be an decent company. I followed the company more
> closely under its previous name, NSTK.
>
> As I recall, the company recently announced a collaboration, which
> is a plus. The company is working to develop RNA-based therapeutics.
> I prefer to invest in late-stage, optionable small cap drug makers
> and MRNA. Since most, if not all, of MRNA's drugs are in very early
> stages, the company is not on my radar.
>
> In this space, MRNA competes with Alnylam (seekingalpha.com/symbo...)
> and a few other companies working to develop RNA-based drugs which
> I cannot recall at this time.
>
> Notable: MRK acquired RNA Therapeutics (seekingalpha.com/symbo...)
> in the fall of 2006.
>
> I liked MRNA when it was very cheap earlier in the year. As for buying
> MRNA right now, I do not have a preference as the company is just
> not on my radar.
>
> From my view, SPPI, ARIA, and other select [late-stage] drug makers
> are more attractive right now.
>
> I hope this helps. Good luck!
>
> Justin
THANK YOU JUSTIN, FOR MY OPINION RIGHT NOW IS THAT THE STOCK PRICE WILL DEPRECIATE BY AT LEAST 25%
BETWEEN NOW, OCTOBER 19TH AND DECEMBER 31ST, 2009. IT IS VERY LOGICAL AND REALISTIC.

On Small Cap Drug Makers and Volatility

Justin Hall, your article is interesting & good reading.
If you ever have a brief few minutes, can you give your
prospective on MDRNA INC(MRNA). IT IS A SMALL CAP, NO SERIOUS REVENUE, PLENTY OF EXPENSES, BUT PLENTY OF IN VIVO NEWS. WITH $4 DOLLAR TARGET PRICES BY RESEARCH FIRMS, AND SINCE 'MRNA' IS AT $1.33 RIGHT NOW ON 10/17/09, DOESN'T IT POSE A BUYING OPPORTUNITY OR SHOULD INVESTORS WAIT UNTIL YEAR END WHEN IT MAY BE AROUND. $92 CENTS?
WHAT DO YOU THINK JUSTIN?
LETS HAVE IT STRAIGHT!

Q1 2009 Biotech Earnings Roundup: The Good, the Bad, and the Ugly

MARK CIFRA-Since you are so informative to many investors, and helpful, I see you left out one stock that needs to be addressed please.
It cerntainly should fit one of your scenario's above.
THE GOD, THE BAD OR THE UGLY
Please give your perspective
on MDRNA INC(MRNA)
APPRECIATED IN ADVANCE!

FDA, Clinical Trial Updates: JNJ, INCY, MEDX, CYTX, AGN, PPHM

Good report Mike as usal. I would like to know Mike,if you, or Adam Feuerstein, or Shulman, or any other Biotech/Pharma writer, would finally
give a proper prospective to invesotrs on 'MRNA'.
There are so many other companies that you report on, Adam reports on, and even Shulman reports on, that warrant a serious look at potentially investing in them. Month after Month
you actually come up with key companies, and reasons why investors should take a second look at these very special companies.. And each of them vary in stock price from low to medium prices. But when investors become obsessed with a stock soley because of potential and because of a cheap price, they possibly are tying their money up in the wrong company and for great lengths of time. By doing so, there is no guarantee of success, and long term the risk factor may deminish more than half their investment overall.
CAN YOU OR SOMEONE WITH YOUR BACKGROUND AND KNOWLEDGE, EMBELLISH YOUR PERSPECTIVE ON
MDRNA INC(MRNA) TO MAKE INVESTORS AWARE OF THE REAL DANGERS AFFILIATED WITH INVESTING WITH 'MRNA' AT THIS CURRENT TIME.
It would be a great public service to all
THANK YOU